Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.
Arvinas is seeking a talented, innovative, and experienced biologist to investigate how targeted-protein degradation can impact neurodegenerative diseases. Successful candidates should be highly motivated and enjoy working in a team-based environment.
This position is laboratory-based and requires strong experimental skills with a background in cell biology, particularly with primary neuronal cultures, and experience in quantitative assay development, cell-based compound screening, biochemical assays, immunocytochemistry, and high-content imaging.
EDUCATION AND TRAINING:
REQUIRED SKILLS AND ABILITIES:
New Haven, CT
Please send CV and cover letter to: firstname.lastname@example.org.